NeoGenomics, Inc.

NeoGenomics provides one of the world’s most comprehensive oncology-focused testing menus to support diagnosis and treatment decisions in cancer care. Its portfolio includes over 500 advanced tests spanning all major molecular modalities. The company partners extensively with biopharma firms to accelerate drug development via companion diagnostics and biomarker-driven clinical trials. It also leverages a large proprietary oncology database (>2 million patients) to power informatics solutions supporting precision medicine initiatives. Recent innovations include the PanTracer™ genomic profiling suite and Paletrra™ spatial proteomic solution. The company continues expanding its capabilities through acquisitions (e.g., Pathline LLC) and strategic partnerships (e.g., Adaptive Biotechnologies for MRD monitoring).